肺腺癌靶向治疗后小细胞肺癌转化的病例报道被引量：7

Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

下载PDF

导出

摘要近年来,非小细胞肺癌(non-small cell lung cancer,NSCLC)静脉化疗逐渐进入平台期,缓解率(response rate,RR)、平均总生存期(overall survival,OS)无明显改善;随着分子生物学发展,以表皮生长因子受体(epidermal growth factor receptor,EGFR)为靶点的EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors,EGFRTKIs)在NSCLC的治疗中疗效显著,但患者最终均会出现耐药,关于耐药机制目前尚未完全明确。本文详细报道1例49岁女性EGFR基因19外显子缺失突变肺腺癌患者,在靶向治疗耐药后二次活检发现转化为小细胞肺癌(small cell lung cancer,SCLC),予以SCLC化疗方案两周期有效;通过分析患者诊疗过程、疗效,对相关机制进展作一综述。 In recent years, the chemotherapy of non-small cell lung cancer （NSCLC） has almost been reached a platform stage, and there is no obvious progress in terms of response rate （RR） and overall survival （OS）; With the great devel- opment of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKIs） has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant （19-DEL） treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer （SCLC） had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.

作者薛淑萍俞婷婷张琰单莉

机构地区新疆医科大学附属肿瘤医院肺内一科

出处《中国肺癌杂志》 CAS CSCD 北大核心 2015年第10期656-660,共5页 Chinese Journal of Lung Cancer

关键词肺肿瘤 EGFR基因突变耐药 Lung neoplsms EGFR mutation Resistance

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献23

1Ferlay J, Shin HR, Bray F, et al. Estimates of wordwide burden of cancerin 2008: GLOBOCAN 2008. IntJ Cancer, 2010, 127(12): 2893-2917.
2Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000, 19(13): 3159-3167.
3Engelman JA, Jiinne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med, 2005, 26(3 ): 314-322.
4Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Y EnglJ Med, 2009, 361(10): 947-957.
5Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
6Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-ceU lung cancer (NSCLC). Ann Oncol, 2013, 24(6): 1615-1622.
7Wood DE. National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Tnorac Surg Clin, 2015, 25(2): 185-197.
8Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Meal, 2011, 3(75): 75ra26.
9Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet, 2012, 44(10): 1111-1116.
10Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR- mutant lung cancers. Clin Cancer Res, 2013, 19(8): 2240-2247.